Organic metal halides
![eMolecules 12012-95-2 | [Pd(allyl)Cl]2 | Ambeed365.890 | C6H10Cl2Pd2 | 97.000 | [Cl-].[Cl-].[Pd+]CC=C.[Pd+]CC=C | 1g | 552711525](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000166055.jpg-250.jpg)
eMolecules 12012-95-2 | [Pd(allyl)Cl]2 | Ambeed365.890 | C6H10Cl2Pd2 | 97.000 | [Cl-].[Cl-].[Pd+]CC=C.[Pd+]CC=C | 1g | 552711525
[Pd(allyl)Cl]2 | Ambeed | 12012-95-2365.890 | C6H10Cl2Pd2 | 97.000 | [Cl-].[Cl-].[Pd+]CC=C.[Pd+]CC=C | 1g | 552711525
Medchemexpress LLC Sepantronium (bromide) | 781600-92-9 | >98% | 750.56 | 25MG
Sepantronium bromide (YM155) is a small molecule inhibitor of survivin, a member of the inhibitor of apoptosis protein (IAP) family. It exhibits potent anticancer activity by suppressing survivin expression, leading to apoptosis in various cancer cell lines.
- Small molecule inhibitor of survivin
- IC50 of 0.54 nM in a cell-free assay
- Potent anticancer activity
- Suppresses survivin expression
- Leads to apoptosis in various cancer cell lines
- Under clinical investigation for the treatment of various cancers
Sigma Aldrich Fine Chemicals Biosciences Cyclohexylmagnesium chloride solution 1.0 M in 2-methyltetrahydrofuran | 931-51-1 | MFCD00003816 | 800ML
Cyclohexylmagnesium chloride solution 1.0 M in 2-methyltetrahydrofuran | Mol Wt: 142.91 | 931-51-1 | MFCD00003816 | 800ML
eMolecules 83948-53-2 | 3-(Boc-amino)propyl bromide | ChemScene | MFCD02683429 | 238.125 | C8H16BrNO2 | 95.000 | CC(C)(C)OC(=O)NCCCBr | 10g | 486157772
3-(Boc-amino)propyl bromide | ChemScene | 83948-53-2 | MFCD02683429 | 238.125 | C8H16BrNO2 | 95.000 | CC(C)(C)OC(=O)NCCCBr | 10g | 486157772
eMolecules Sodium 2-(2-((2,6-dichlorophenyl)amino)phenyl)acetate | 15307-79-6 | 5G | Purity: 95%
Matrix Scientific | Sodium 2-(2-((2,6-dichlorophenyl)amino)phenyl)acetate | 5G | 15307-79-6 | MFCD00082251
If you are unable to find the chemical you are looking for, make sure you are logged into your fishersci.com account and click on the following link:
eMolecules Building Block Tool
Medchemexpress LLC Bromocholine (bromide) | 2758-06-7 | 98.0% | 246.97 | 25 G
2-Bromo-N,N,N-trimethylethanaminium bromide is a quaternary ammonium salt frequently utilized as a phase transfer catalyst in organic chemical reactions, aiding in the transfer of reactants between immiscible phases. It can also serve as a halogenating agent, for instance, in the bromination of olefins. For research use only, this product is not sold to patients.
- Biochemical reagent
- Can be used as a biological material or organic compound for life science related research.
Medchemexpress LLC Atropine methyl bromide | 2870-71-5 | 99.8% | 384.31 | 25 MG
Atropine methyl bromide is a muscarinic receptor (mAChR) antagonist. It is a quaternary ammonium salt of atropine and acts as a mydriatic for pupil dilation during ophthalmic examinations. Due to its highly polar nature, it is used to relieve pyloric spasms in infants and penetrates the central nervous system less readily than atropine.
- Acts as a muscarinic receptor antagonist
- Used as a mydriatic for pupil dilation
- Relieves pyloric spasm in infants
- Less central nervous system penetration compared to atropine due to high polarity
![eMolecules 1643-19-2 | Tetrabutylammonium bromide | Oakwood Chemicals | MFCD00011633 | 322.375 | C16H36BrN | 99.000 | [Br-].CCCC[N+](CCCC)(CCCC)CCCC | 500g | 480169577](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000170328.jpg-250.jpg)
eMolecules 1643-19-2 | Tetrabutylammonium bromide | Oakwood Chemicals | MFCD00011633 | 322.375 | C16H36BrN | 99.000 | [Br-].CCCC[N+](CCCC)(CCCC)CCCC | 500g | 480169577
Tetrabutylammonium bromide | Oakwood Chemicals | 1643-19-2 | MFCD00011633 | 322.375 | C16H36BrN | 99.000 | [Br-].CCCC[N+](CCCC)(CCCC)CCCC | 500g | 480169577
Medchemexpress LLC Tarloxotinib bromide | 1636180-98-7 | 98.8% | 681.77 | 10 MG
Tarloxotinib bromide is an irreversible EGFR/HER2 inhibitor intended for research use only. It is metabolized efficiently under hypoxia in human NSCLC cell lines, a process inhibited by oxygen. This product demonstrates greater activity compared with erlotinib.
- Irreversible EGFR/HER2 inhibitor.
- Hypoxia-activated.
- Effective in inhibiting WT EGFR in vivo.
- Shown to be metabolized efficiently under hypoxia.
- Overcomes erlotinib-resistance in preclinical NSCLC models.
- Associated with tumor regression and durable inhibition of WT EGFR tumor phosphorylation in xenograft models.
eMolecules 83948-53-2 | 3-(Boc-amino)propyl bromide | Ambeed | MFCD02683429 | 238.125 | C8H16BrNO2 | 98.000 | CC(C)(C)OC(=O)NCCCBr | 10g | 525134483
3-(Boc-amino)propyl bromide | Ambeed | 83948-53-2 | MFCD02683429 | 238.125 | C8H16BrNO2 | 98.000 | CC(C)(C)OC(=O)NCCCBr | 10g | 525134483
Medchemexpress LLC Tarloxotinib bromide | 1636180-98-7 | 97.2% | 681.77 | 25 MG
Tarloxotinib bromide (TH-4000) is an irreversible EGFR/HER2 inhibitor. It is a hypoxia-activated irreversible EGFR-TKI that has shown greater activity compared to erlotinib in preclinical NSCLC models. It has been shown to be metabolized efficiently under hypoxia in human NSCLC cell lines. Tarloxotinib bromide treatment can also regress WT EGFR NSCLC tumor models H125 and H1648 in vivo. It is for research use only and not sold to patients.
- Irreversible EGFR/HER2 inhibitor
- Hypoxia-activated irreversible EGFR-TKI
- Greater activity compared to erlotinib in preclinical NSCLC models
- Metabolized efficiently under hypoxia in human NSCLC cell lines
- Can regress WT EGFR NSCLC tumor models H125 and H1648 in vivo
- For research use only
Medchemexpress LLC Dicetyldimonium bromide | 70755-47-4 | 99.7% | 574.86 | 50 G
Dicetyldimonium bromide is a biochemical reagent utilized in life science research. It serves as a foundational material for various biological and organic applications.
- Functions as a biological material.
- Functions as an organic compound.
- Supports life science related research.
Medchemexpress LLC Tarloxotinib bromide | 1636180-98-7 | 98.8% | 681.77 | 50 MG
Tarloxotinib bromide (TH-4000) is an irreversible EGFR/HER2 inhibitor. It functions as a hypoxia-activated irreversible EGFR-TKI, demonstrating greater activity than erlotinib and exhibiting the therapeutic index necessary to inhibit WT EGFR in vivo, as evidenced by its ability to regress WT EGFR NSCLC tumor models. This product is intended for research use only.
- Irreversible EGFR/HER2 inhibitor
- Hypoxia-activated EGFR-TKI
- Greater activity compared with erlotinib
- Capable of regressing WT EGFR NSCLC tumor models